Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 9, 2013 - Issue 10
Submit an article Journal homepage
1,190
Views
19
CrossRef citations to date
0
Altmetric
Drug Evaluations

The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma

Chiara PautassoUniversity of Torino, Division of Hematology, Myeloma Unit, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy+39 01 1663 5814; +39 01 1696 3737; [email protected]
,
Sara BringhenUniversity of Torino, Division of Hematology, Myeloma Unit, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy+39 01 1663 5814; +39 01 1696 3737; [email protected]
,
Chiara CerratoUniversity of Torino, Division of Hematology, Myeloma Unit, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy+39 01 1663 5814; +39 01 1696 3737; [email protected]
,
Valeria MagarottoUniversity of Torino, Division of Hematology, Myeloma Unit, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy+39 01 1663 5814; +39 01 1696 3737; [email protected]
&
Antonio PalumboUniversity of Torino, Division of Hematology, Myeloma Unit, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy+39 01 1663 5814; +39 01 1696 3737; [email protected]
Pages 1371-1379 | Published online: 09 Jul 2013

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Muhamed Baljevic & Robert Z. Orlowski. (2019) Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism & Toxicology 15:6, pages 459-473.
Read now
Paul G Richardson, Jacob P Laubach, Sagar Lonial, Philippe Moreau, Sung-Soo Yoon, Vânia TM Hungria, Meletios A Dimopoulos, Meral Beksac, Melissa Alsina & Jesús F San-Miguel. (2015) Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Review of Anticancer Therapy 15:7, pages 737-748.
Read now
Cristina Meregalli, Alessia Chiorazzi, Valentina A Carozzi, Annalisa Canta, Barbara Sala, Matteo Colombo, Norberto Oggioni, Cecilia Ceresa, Dana Foudah, Federica La Russa, Mariarosaria Miloso, Gabriella Nicolini, Paola Marmiroli, David LH Bennett & Guido Cavaletti. (2014) Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy. Cell Cycle 13:4, pages 612-621.
Read now

Articles from other publishers (16)

Da-cai Xu, Li Yang, Pei-quan Zhang, Ding Yan, Qian Xue, Qing-tian Huang, Xiao-fen Li, Ya-li Hao, Dao-lin Tang, Q. Ping Dou, Xin Chen & Jin-bao Liu. (2021) Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment. Acta Pharmacologica Sinica 43:8, pages 2128-2138.
Crossref
Jaydeep K. Srimani, Paul M. Diderichsen, Michael J. Hanley, Karthik Venkatakrishnan, Richard Labotka & Neeraj Gupta. (2022) Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients. CPT: Pharmacometrics & Systems Pharmacology 11:8, pages 1085-1099.
Crossref
Naveen Kumar Perumal, Nivya Vijayan, Madan Kumar Perumal, Devaraj Halagowder & Niranjali Devaraj Sivasithamparam. 2022. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 761 773 .
Naveen Kumar Perumal, Nivya Vijayan, Madan Kumar Perumal, Devaraj Halagowder & Niranjali Devaraj Sivasithamparam. 2021. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 1 14 .
Aseel Alsouqi, Muhammad Khan, Binod Dhakal, Liping Du, Shelton Harrell, Parameswaran Hari & Robert F. Cornell. (2021) KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. Clinical Lymphoma Myeloma and Leukemia 21:8, pages 526-535.
Crossref
Yifei Xie, Ke Yao, Zigang Dong & Kangdong Liu. (2021) Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms. Cancer Letters 510, pages 1-12.
Crossref
Changjiang Zhang, Xiuxiu Wang, Ru Cheng & Zhiyuan Zhong. (2020) A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo. Biomacromolecules 21:6, pages 2049-2059.
Crossref
Robert F. Cornell, Bonnie Ky, Brendan M. Weiss, Cherie N. Dahm, Deepak K. Gupta, Liping Du, Joseph R. Carver, Adam D. Cohen, Brian G. Engelhardt, Alfred L. Garfall, Stacey A. Goodman, Shelton Lacy Harrell, Adetola A. Kassim, Trafina Jadhav, Madan Jagasia, Javid Moslehi, Rupal O’Quinn, Michael R. Savona, David Slosky, Amanda Smith, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman & Daniel Lenihan. (2019) Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology 37:22, pages 1946-1955.
Crossref
Turgut E. Aktepe, Susann Liebscher, Julia E. Prier, Cameron P. Simmons & Jason M. Mackenzie. (2017) The Host Protein Reticulon 3.1A Is Utilized by Flaviviruses to Facilitate Membrane Remodelling. Cell Reports 21:6, pages 1639-1654.
Crossref
Ahad Lodhi, Abhishek Kumar, Muhammad U. Saqlain & Manish Suneja. (2015) Thrombotic microangiopathy associated with proteasome inhibitors. Clinical Kidney Journal 8:5, pages 632-636.
Crossref
Meirong Zang, Zengjun Li, Lanting Liu, Fei Li, Xin Li, Yun Dai, Wei Li, Ulrike Kuckelkorn, Thorsten R. Doeppner, Dirk M. Hermann, Wen Zhou, Lugui Qiu & Fengyan Jin. (2015) Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Cancer Letters 366:2, pages 173-181.
Crossref
Guang Yang, Minjie Gao, Yiwen Zhang, Yuanyuan Kong, Lu Gao, Yi Tao, Ying Han, Huiqun Wu, Xiuqin Meng, Hongwei Xu, Fenghuang Zhan, Xiaosong Wu & Jumei Shi. (2015) Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget 6:29, pages 26982-26994.
Crossref
Matthew Trendowski. (2015) PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction. Pharmacological Research 99, pages 202-216.
Crossref
Lydia Mata-Cantero, Sofía Lobato-Gil, Fabienne Aillet, Valérie Lang & Manuel S. Rodriguez. 2015. Stress Response Pathways in Cancer. Stress Response Pathways in Cancer 225 264 .
Mark S. Butler, Avril A. B. Robertson & Matthew A. Cooper. (2014) Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31:11, pages 1612-1661.
Crossref
Hermann Einsele. 2014. Small Molecules in Oncology. Small Molecules in Oncology 325 345 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.